Similar articles for PMID: 11718433

Year	Number of Results
1997	2
1998	5
1999	2
2000	5
2001	16
2002	17
2003	8
2004	16
2005	17
2006	15
2007	14
2008	13
2009	14
2010	8
2011	10
2012	10
2013	7
2014	3
2015	1
2016	1
2018	2
2019	4
2020	1
2021	2
2022	7
2023	4
2024	0

1

Role of alendronate and risedronate in preventing and treating osteoporosis.

Peters ML, Leonard M, Licata AA. Peters ML, et al. Cleve Clin J Med. 2001 Nov;68(11):945-51. doi: 10.3949/ccjm.68.11.945. Cleve Clin J Med. 2001. PMID: 11718433 Free article. Review.

2

Risedronate: a new oral bisphosphonate.

Umland EM, Boyce EG. Umland EM, et al. Clin Ther. 2001 Sep;23(9):1409-21. doi: 10.1016/s0149-2918(01)80116-8. Clin Ther. 2001. PMID: 11589256 Review.

3

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.

Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators. Rosen CJ, et al. J Bone Miner Res. 2005 Jan;20(1):141-51. doi: 10.1359/JBMR.040920. Epub 2004 Sep 29. J Bone Miner Res. 2005. PMID: 15619680 Free article. Clinical Trial.

4

Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.

Iwamoto J, Takeda T, Sato Y. Iwamoto J, et al. Expert Opin Pharmacother. 2007 Nov;8(16):2743-56. doi: 10.1517/14656566.8.16.2743. Expert Opin Pharmacother. 2007. PMID: 17956196 Review.

5

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y. Iwamoto J, et al. Curr Med Res Opin. 2006 May;22(5):919-28. doi: 10.1185/030079906X100276. Curr Med Res Opin. 2006. PMID: 16709313 Review.

6

Bisphosphonates for osteoporosis.

[No authors listed] [No authors listed] Drug Ther Bull. 2001 Sep;39(9):68-72. doi: 10.1136/dtb.2001.39968. Drug Ther Bull. 2001. PMID: 11586803 Review.

7

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.

Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE; Fosamax Actonel Comparison Trial investigators. Sebba AI, et al. Curr Med Res Opin. 2004 Dec;20(12):2031-41. doi: 10.1185/030079904x16768. Curr Med Res Opin. 2004. PMID: 15706659 Clinical Trial.

8

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.

Ringe JD, Möller G. Ringe JD, et al. Rheumatol Int. 2009 Dec;30(2):213-21. doi: 10.1007/s00296-009-0940-5. Rheumatol Int. 2009. PMID: 19430791

9

Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.

Emkey R. Emkey R. MedGenMed. 2004 Jul 19;6(3):6. MedGenMed. 2004. PMID: 15520628 Free PMC article. Review.

10

Gastroenterologists and choosing the right bisphosphonate.

Leder BZ, Kronenberg HM. Leder BZ, et al. Gastroenterology. 2000 Sep;119(3):866-9. doi: 10.1053/gast.2000.17841. Gastroenterology. 2000. PMID: 10982780 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

184 results

Results by year